Special ReportsAll NewsFDA BriefsOncology IconsThe Targeted PulseVoices from the Field
Conference CoverageConference ListingData Dialogue with the Oncology Brothers
All VideosCase-Based Peer PerspectivesEvolving Paradigms in OncologyExpert Perspective Virtual Tumor BoardInterviewsInvestigator PerspectivesMedical World NewsPersonalized MedicinePivotal Practice Views with the Oncology BrothersPodcastsSpeaking Out
All PublicationsEvolving ParadigmsPeers & Perspectives in OncologyTargeted Therapies in Oncology
CASE-BASED ROUNDTABLEPARTNERS
CME/CEClinical TrialsEventsPrecision Medicine PerspectivesPress ReleasesSponsored ContentTreatment Resources
SUBSCRIBE
BRAIN CANCER
BREAST CANCERBREAST CANCER
GENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERS
GENOMIC TESTINGGENOMIC TESTING
GI CANCERSGI CANCERSGI CANCERSGI CANCERSGI CANCERS
GYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERS
HEAD & NECK CANCERS
HEMATOLOGYHEMATOLOGY
IMMUNOTHERAPYIMMUNOTHERAPY
LEUKEMIASLEUKEMIASLEUKEMIASLEUKEMIAS
LUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCER
LYMPHOMASLYMPHOMASLYMPHOMASLYMPHOMAS
MPNs
MULTIPLE MYELOMA
NTRK GENE FUSIONS
SARCOMA
SKIN CANCERSSKIN CANCERS
THYROID CANCERS
Spotlight -
  • Biomarker-Driven Lung Cancer
  • GIST
  • HER2 Breast Cancer
  • Chronic Lymphocytic Leukemia
  • Small Cell Lung Cancer
  • Renal Cell Carcinoma
BRAIN CANCER
BREAST CANCERBREAST CANCER
GENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERS
GENOMIC TESTINGGENOMIC TESTING
GI CANCERSGI CANCERSGI CANCERSGI CANCERSGI CANCERS
GYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERS
HEAD & NECK CANCERS
HEMATOLOGYHEMATOLOGY
IMMUNOTHERAPYIMMUNOTHERAPY
LEUKEMIASLEUKEMIASLEUKEMIASLEUKEMIAS
LUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCER
LYMPHOMASLYMPHOMASLYMPHOMASLYMPHOMAS
MPNs
MULTIPLE MYELOMA
NTRK GENE FUSIONS
SARCOMA
SKIN CANCERSSKIN CANCERS
THYROID CANCERS
    • CASE-BASED ROUNDTABLE
    • PARTNERS
    • SUBSCRIBE
Advertisement

A 67-Old Woman with Cervical Cancer : Episode 7

Managing Treatment-Related Side Effects of Tisotumab Vedotin

October 2, 2023
By Ramez N. Eskander, MD
News
Video

Ramez N. Eskander, MD, discusses the importance of understanding and managing treatment-related adverse events, including ocular side effects, bleeding, and neuropathy, associated with the innovative therapy tisotumab vedotin in cervical cancer patients.

EP: 1.Navigating Complex Cervical Cancer Cases: Therapeutic Challenges and Innovations

EP: 2.HPV and Cervical Cancer: Prevention and Screening Strategies

EP: 3.Biomarkers in Cervical Cancer: Guiding Innovative Treatments

EP: 4.Revolutionizing Frontline Cervical Cancer Treatment: Trials to Transformative Therapies

EP: 5.Recurrent Cervical Cancer Treatment Evolution: Immunotherapy and Beyond

EP: 6.Tisotumab Vedotin: Advancing Cervical Cancer Treatment

Now Viewing

EP: 7.Managing Treatment-Related Side Effects of Tisotumab Vedotin

EP: 8.Innovations in Cervical Cancer Treatment: Exploring Tisotumab Vedotin Combinations

Transcript:

Ramez N. Eskander, MD: But in the same breath we [must] be knowledgeable about what patients might experience as treatment-related [adverse] effects on therapy. So, when we are talking about tisotumab vedotin, this antibody-drug conjugate that targets tissue factors, there were some prespecified adverse events of interest, ocular [adverse] effects, and there are specific ocular mitigation strategies. Bleeding. Why? Because tissue factor is part of the collaboration cascade and they wanted to make sure there were no significant bleeding events, and then neuropathy because the payload is a microtubule-disrupting payload.

And thankfully, when you looked across the board, particularly at bleeding and neuropathy, the majority were grade 1: so, 17% grade 1 neuropathy rate, 34% grade 1 bleeding epistaxis. And then you talked about ocular AEs, 25% grade 1 ocular adverse events, 27% grade 2. So, what does this mean? It means that we [must] be thoughtful and educate ourselves as providers or colleagues to understand what treatment-related adverse events may arise on therapy. And again, we’re thinking about those key ones. That neuropathy, the ocular treatment-related adverse events, grade 3 adverse events independent of that. Anemia, 1%. Asthenia, 1%. Pruritus, 1%. Very uncommon, which is reassuring as we look to employ this as a treatment strategy. But it’s key to educate our patients. It’s key to have a team that can help manage treatment-related [adverse] effects that come up, because the reality is that the patient is educated, prepared, and we have a treatment program that can help them get through the adverse event, they can stay on an effective treatment as long as they’re benefiting.

And really that’s the priority. What we don’t want is to have a patient come off treatment because of a treatment-related adverse event, although they’re benefiting from study. That would be disappointing for us because we would theoretically lose a therapeutic treatment opportunity. With respect to the ocular [adverse] effects for tisotumab vedotin, thankfully there is great education that’s provided—both available to us as providers, but also in the package insert for the medication that really details what needs to be done. Ophthalmic eye exams; they don’t have to be with an ophthalmologist, they can be with an optometrist or an ophthalmologist, whoever is available, and that’s visual acuity and slit lamp.

There [are] specific criteria for topical corticosteroid eye drops that can be used during therapy as well as vasoconstricting eye drops and lubricating eye drops. So lubricating eye drops, corticosteroid eye drops, and vasoconstricting eye drops. And cold caps. Patients apply cold caps to cover their eyes during therapy, and that helps reduce the risk of ocular adverse events. And again, important for lubricating eye drops. And if there’s anything else that could theoretically impact vision or cause greater irritation such as contact lenses, we try to educate our patients to avoid that. And I mentioned earlier, I just want to highlight again, that the innovaTV 301 press release was positive. The confirmatory trial that really helps innovaTV 204, we eagerly await the presentation of [those] data informing the benefit of tisotumab vedotin over physician’s choice chemotherapy.

Transcript is AI generated and edited for readability.

Newsletter

Stay up to date on practice-changing data in community practice.

Subscribe Now!
Recent Videos
1 expert in this video
1 expert in this video
1 expert in this video
Related Content

FDA Fast-Tracks Novel ADC in Cervical Cancer

FDA Fast-Tracks Novel ADC in Cervical Cancer

Sabrina Serani
May 9th 2025
Article

ADRX-0706, a Nectin-4-targeted antibody-drug conjugate, has earned FDA fast track designation in advanced cervical cancer.

Read More


Westin Discusses Logistical and Tolerability Challenges in Metastatic Cervical Cancer

Westin Discusses Logistical and Tolerability Challenges in Metastatic Cervical Cancer

Targeted Oncology Staff
April 21st 2025
Article

During a live event, Shannon N. Westin, MD, MPH, and participants discussed their experience treating patients with progressive cervical cancer and the toxicity profile of tisotumab vedotin.

Read More


Seeking Optimal Combinations and Treatment Sequencing in Cervical Cancer

Seeking Optimal Combinations and Treatment Sequencing in Cervical Cancer

Tony Berberabe, MPH
February 11th 2025
Article

Chemoradiation with platinum-based chemo is standard for locally advanced cervical cancer, but adverse events drive exploration of immunotherapy and optimal treatment sequences.

Read More


Participants Discuss Frontline Immunotherapy Followed by ADC for Metastatic Cervical Cancer

Participants Discuss Frontline Immunotherapy Followed by ADC for Metastatic Cervical Cancer

Targeted Oncology Staff
December 19th 2024
Article

During a Case-Based Roundtable® event, Ramez N. Eskander, MD, and participants discussed first and second-line therapy decisions for a patient with PD-L1–positive cervical cancer in the frontline metastatic setting.

Read More


FDA Grants CRB-701 Fast Track Status in R/R Cervical Cancer

FDA Grants CRB-701 Fast Track Status in R/R Cervical Cancer

Jordyn Sava
December 5th 2024
Article

CRB-701 has gained FDA fast track status for the treatment of adult patients with relapsed/refractory metastatic cervical cancer.

Read More


Pembrolizumab Plus Denileukin Diftitox Shows Promise in Solid Tumors

Pembrolizumab Plus Denileukin Diftitox Shows Promise in Solid Tumors

Jordyn Sava
November 13th 2024
Article

A phase 1 trial of pembrolizumab plus denileukin diftitox shows 27% response and 33% clinical benefit in recurrent solid tumors, with manageable toxicity.

Read More

Related Content

FDA Fast-Tracks Novel ADC in Cervical Cancer

FDA Fast-Tracks Novel ADC in Cervical Cancer

Sabrina Serani
May 9th 2025
Article

ADRX-0706, a Nectin-4-targeted antibody-drug conjugate, has earned FDA fast track designation in advanced cervical cancer.

Read More


Westin Discusses Logistical and Tolerability Challenges in Metastatic Cervical Cancer

Westin Discusses Logistical and Tolerability Challenges in Metastatic Cervical Cancer

Targeted Oncology Staff
April 21st 2025
Article

During a live event, Shannon N. Westin, MD, MPH, and participants discussed their experience treating patients with progressive cervical cancer and the toxicity profile of tisotumab vedotin.

Read More


Seeking Optimal Combinations and Treatment Sequencing in Cervical Cancer

Seeking Optimal Combinations and Treatment Sequencing in Cervical Cancer

Tony Berberabe, MPH
February 11th 2025
Article

Chemoradiation with platinum-based chemo is standard for locally advanced cervical cancer, but adverse events drive exploration of immunotherapy and optimal treatment sequences.

Read More


Participants Discuss Frontline Immunotherapy Followed by ADC for Metastatic Cervical Cancer

Participants Discuss Frontline Immunotherapy Followed by ADC for Metastatic Cervical Cancer

Targeted Oncology Staff
December 19th 2024
Article

During a Case-Based Roundtable® event, Ramez N. Eskander, MD, and participants discussed first and second-line therapy decisions for a patient with PD-L1–positive cervical cancer in the frontline metastatic setting.

Read More


FDA Grants CRB-701 Fast Track Status in R/R Cervical Cancer

FDA Grants CRB-701 Fast Track Status in R/R Cervical Cancer

Jordyn Sava
December 5th 2024
Article

CRB-701 has gained FDA fast track status for the treatment of adult patients with relapsed/refractory metastatic cervical cancer.

Read More


Pembrolizumab Plus Denileukin Diftitox Shows Promise in Solid Tumors

Pembrolizumab Plus Denileukin Diftitox Shows Promise in Solid Tumors

Jordyn Sava
November 13th 2024
Article

A phase 1 trial of pembrolizumab plus denileukin diftitox shows 27% response and 33% clinical benefit in recurrent solid tumors, with manageable toxicity.

Read More

About Us
Advertise
Contact Us
CureToday.com
CancerNetwork.com
OncLive.com
OncNursingNews.com
Do Not Sell My Information
Privacy
Terms & Conditions
Editorial Board
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.